Incyte Tumbles On More Jakafi Trial Terminations
This article was originally published in Scrip
Incyte Corporation is discontinuing all ongoing trials for its Janus kinase inhibitor, Jakafi (ruxolitinib), in solid tumors following poor results in a Phase III study in metastatic pancreatic cancer and in a recently suspended Phase II colorectal cancer trial.
You may also be interested in...
In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.
Losing Medivation could end up being a winning proposition for the French pharma if it can boost its cancer franchise another way, like by acquiring its partner in multiple collaborations Regeneron or making a less expensive takeout, such as Incyte or Ariad.
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.